Sanada Seiko, Tanaka Toshihiko, Kameyoshi Yoshikazu, Hide Michihiro
Department of Dermatology, Programs for Biomedical Research, Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
Arch Dermatol Res. 2005 Sep;297(3):134-8. doi: 10.1007/s00403-005-0586-4. Epub 2005 Sep 29.
Many patients with chronic idiopathic urticaria are not sufficiently controlled with histamine H(1)-receptor antagonists. Leukotriene receptor antagonists have been reported to be effective for certain cases of urticaria, although their proper application remains to be established. To study the effectiveness of montelukast, a leukotriene receptor antagonist, for the treatment of chronic urticaria that was not controlled by histamine H(1)-receptor antagonists. Twenty-five patients with chronic idiopathic urticaria were treated with 10 mg of montelukast for one week or more, without changing any precedent treatment that they were using before the study including histamine H(1)-receptor antagonists. The effectiveness of montelukast for each patient was evaluated and compared with clinical features and/or backgrounds of the patients. Twelve patients, including six who had been treated with corticosteroids, were evaluated as "markedly improved" or "improved" following treatment with montelukast. There was no statistically significant relation of the effectiveness to the complications with non-steroidal anti-inflammatory drugs (NSAIDs) intolerance, mechanical urticaria, or reactions to autologous serum skin test. However, the patients for whom montelukast was effective were younger (33.2+/-16.3 years, mean +/- SD)(P<0.05, Mann-Whitney test) and their duration of illness shorter (15.9+/-18.3 months) (P<0.005, Mann-Whitney test) than those of patients for whom montelukast was ineffective (45.9+/-15.0 years, 89.6+/-71.7 months). Montelukast may be worth trying for patients with chronic idiopathic urticaria, when the condition is not sufficiently controlled with histamine H(1)-receptor antagonists.
许多慢性特发性荨麻疹患者使用组胺H(1)受体拮抗剂治疗效果不佳。白三烯受体拮抗剂据报告对某些荨麻疹病例有效,但其正确应用仍有待确定。为研究白三烯受体拮抗剂孟鲁司特治疗组胺H(1)受体拮抗剂治疗无效的慢性荨麻疹的有效性。25例慢性特发性荨麻疹患者接受10mg孟鲁司特治疗一周或更长时间,且不改变研究前正在使用的任何先前治疗方法,包括组胺H(1)受体拮抗剂。评估孟鲁司特对每位患者的有效性,并与患者的临床特征和/或背景进行比较。12例患者,包括6例曾接受皮质类固醇治疗的患者,在接受孟鲁司特治疗后被评估为“显著改善”或“改善”。有效性与非甾体抗炎药(NSAIDs)不耐受、机械性荨麻疹或自体血清皮肤试验反应等并发症之间无统计学显著相关性。然而,孟鲁司特治疗有效的患者比无效的患者更年轻(平均年龄33.2±16.3岁)(P<0.05,曼-惠特尼检验),病程更短(15.9±18.3个月)(P<0.005,曼-惠特尼检验)(无效患者平均年龄45.9±15.0岁,89.6±71.7个月)。当慢性特发性荨麻疹患者使用组胺H(1)受体拮抗剂治疗效果不佳时,孟鲁司特可能值得一试。